Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sintilimab + S-1 + Oxaliplatin + Nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a multi-drug regimen used in cancer treatment, combining an immunotherapy agent with chemotherapy agents. - **Sintilimab**: A fully human IgG4 monoclonal antibody that binds to PD-1, blocking its interaction with ligands and helping to recover T-cell anti-tumor response. - **S-1**: An oral fluoropyrimidine anticancer agent. - **Oxaliplatin**: A platinum-based chemotherapy drug. - **Nab-paclitaxel**: A nanoparticle albumin-bound formulation of the taxane chemotherapy agent, paclitaxel. The combination appears to be used in the treatment of various cancers, particularly gastrointestinal cancers, leveraging both immune-checkpoint inhibition and cytotoxic chemotherapy mechanisms.
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on Sintilimab + S-1 + Oxaliplatin + Nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sintilimab + S-1 + Oxaliplatin + Nab-paclitaxel.